Skip to main content

Advertisement

SpringerLink
Log in

FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial

  • Rapid Communication
  • Published:
Molecular Imaging and Biology Aims and scope Submit manuscript

Abstract

Introduction

Harnessing the power of molecular imaging in particular positron emission tomography (PET) to assess response to therapy in early clinical trials has the potential to yield crucial data on efficacy and streamline drug development. Vorinostat (also known as SAHA, suberoylanilide hydroxamic acid) is a histone deacetylase (HDAC) inhibitor which alters gene transcription to inhibit proliferation and promote apoptosis.

Methods

In a phase II trial of vorinostat for cutaneous T cell lymphoma (CTCL), 2-deoxy-2-[F-18]fluoro-d-glucose (FDG)-PET/computed tomography (CT) was performed on patients with both cutaneous and nodal disease. FDG-PET/CT fuses the power of metabolic imaging from FDG-PET with the anatomic detail of CT. Scans were conducted on subjects pre-therapy and during therapy.

Results

Changes in the values of FDG uptake and measurements of nodal dimensions and thickness of cutaneous lesions were tabulated. FDG-PET/CT provided an objective measure of the response (or lack thereof) of both cutaneous and nodal disease to therapy with vorinostat. The results of this study are encouraging for the potential utility of FDG-PET/CT in future trials with HDAC inhibitors for other diseases and for CTCL with other therapies.

Conclusion

Further study will be required to determine the prognostic value of the initial PET/CT scan and response on follow-up scans.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13
Fig. 14
Fig. 15

References

  1. Shapiro M, Yun M, Junkins-Hopkins JM et al (2002) Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas. J Am Acad Dermatol 47:623–628

    Article  PubMed  Google Scholar 

  2. Valencak J, Becherer A, Der-Petrossian M, Trautinger F, Raderer M, Hoffmann M (2004) Positron emission tomography with [18F] 2-fluoro-d-2-deoxyglucose in primary cutaneous T-cell lymphomas. Haematologica 89:115–116

    PubMed  Google Scholar 

  3. Tsai EY, Taur A, Espinosa L et al (2006) Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol 142:577–584

    Article  PubMed  Google Scholar 

  4. Kuo PH, McClennan BL, Carlson K et al (2008) FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma. Mol Imaging Biol 10:74–81

    Article  PubMed  Google Scholar 

  5. Liu T, Kuljaca S, Tee A, Marshall GM (2006) Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 32:157–165

    Article  PubMed  Google Scholar 

  6. Vigushin DM, Coombes RC (2002) Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13:1–13

    Article  PubMed  CAS  Google Scholar 

  7. Garcia-Manero G, Issa JP (2005) Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Invest 23:635–642

    Article  PubMed  CAS  Google Scholar 

  8. Kelly WK, Marks PA (2005) Drug insight: histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2:150–157

    Article  PubMed  CAS  Google Scholar 

  9. Duvic M, Talpur R, Ni X et al (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31–39

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diagnostic Radiology, Yale University School of Medicine and Yale New Haven Hospital, New Haven, 06520-8059, CT, USA

    Phillip H. Kuo & Kacie R. Carlson

  2. Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA

    Inger Christensen, Michael Girardi & Peter W. Heald

Authors
  1. Phillip H. Kuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kacie R. Carlson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Inger Christensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Girardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter W. Heald
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Phillip H. Kuo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kuo, P.H., Carlson, K.R., Christensen, I. et al. FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial. Mol Imaging Biol 10, 306–314 (2008). https://doi.org/10.1007/s11307-008-0161-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11307-008-0161-4

Key words

Search

Navigation